An assessment of canine ectoparasiticide administration compliance in the USA

Parasites & Vectors

Table 5 Proportion of each two-dose plus purchase gap interval with and without ectoparasite protection

Protection duration (nominal months)	Product	Fluralaner^a (12-week dosing)		Product	Afoxolaner^b		Lotilaner^b		Sarolaner^b
Protection duration (nominal months)	Fluralaner gaps	Doses plus gap period^c (weeks)	Percentage of time protected	Monthly product gaps	Doses plus gap period^c (weeks)	Percentage of time protected	Doses plus gap period^c (weeks)	Percentage of time protected	Doses plus gap period^c (weeks)	Percentage of time protected
1	No gap^b			No Gap
2				Dose 1–2	21.5	40	17.5	49	28.9	30
3				Dose 2–3	18.5	46	15.1	57	25.0	34
4	1–2 Doses	36.8	65	Dose 3–4	18.7	46	15.0	57	26.2	33
5				Dose 4–5	15.6	55	13.0	66	21.5	40
6				Dose 5–6	14.3	60	12.6	68	19.3	45
7	2–3 Doses	32.5	74	Dose 6–7	17.7	49	18.4	47	28.0	31
8				Dose 7–8	12.9	67	12.5	69	17.4	49
9				Dose 8–9	12.0	72	11.7	74	17.2	50
10	3–4 Doses	28.8	83	Dose 9–10	12.0	72	12.6	68	18.9	46
11				Dose 10–11	10.9	79	11.2	77	15.5	55
12	4–5 Doses^d	27.3	88	Dose 11–12	10.7	80	10.2	84	12.2	70

^aFor fluralaner, the single dose duration of efficacy was 12 weeks per label indication for most parasites, with no gap
^bFor afoxolaner, lotilaner and sarolaner, the single dose duration of efficacy was 4.3 weeks, with no gap
^cDoses plus gap period is the duration encompassing the ectoparasite protection interval for the two doses, as indicated by the product label, plus the average gap between the purchase of these two doses
^dFour to five doses of fluralaner provided ectoparasiticide protection beyond the 12-month study duration

ISSN: 1756-3305